Isofol Medical AB (publ) announced that the company has received additional results from the laboratory tests conducted with arfolitixorin ahead of a potential decision on the drug candidate's continued clinical development. The results show interesting supplementary effects of arfolitixorin in two of a total of five evaluated organoids from colorectal cancer tumors. These findings are positive for Isofol and the company will implement additional bioinformatic analysis to identify potential patterns.

Isofol has received further results from the laboratory tests carried out as part of the company's stepwise process to enable a cost-effective evaluation of the drug candidate arfolitixorin. The results originate from tests on organoids from tumors in the colon and rectum and show additional effects of arfolitix orin in two of a totalof five organoids studied, an effect that was not seen with leucovorin. The additional effect was shown as an enhancement of the response to the chemotherapy drug 5-FU, both in terms of reducing tumor size and the ability to induce cell death.

In three out of five organoid tests, however, no additional effect of any of the folates in combination with 5-FU was seen. Data from the laboratory tests will undergo bioinformatics analyses to identify molecular patterns associated with folate sensitivity. These analyses may provide further support in the construction of a hypothesis for the continued development of arfolitixor in.